Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
Author: Benzinga Newsdesk | July 01, 2024 02:57am
Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.
Posted In: MESO